학술논문

O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs
Document Type
Abstract
Source
In Annals of Oncology July 2021 32 Supplement 3:S217-S218
Subject
Language
ISSN
0923-7534